| Name | Title | Contact Details |
|---|
Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc.
LigoCyte Pharmaceuticals, Inc is a Bozeman, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tripos, L.P. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Raptor is a NASDAQ-listed biopharmaceutical company with the mission to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases. Raptor`s lead product, PROCYSBI (cysteamine bitartrate) delayed-release capsules, received FDA approval on April 30, 2013. The Company anticipates receiving a determination from the EMA regarding its PROCYSBI marketing application in the European Union in the second half of 2013. Raptor’s product pipeline may advance therapeutic options for additional indications. Raptor`s management team consists of repeat entrepreneurs with the experience to build a successful company.
Mid Atlantic Technology and Enviromental Research In is a Castle Hayne, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.